| Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications G Marucci, D Dal Ben, M Buccioni, A Martí Navia, A Spinaci, R Volpini, ... Expert opinion on therapeutic patents 29 (12), 943-963, 2019 | 39 | 2019 |
| Adenosine receptors as neuroinflammation modulators: Role of A1 agonists and A2A antagonists A Martí Navia, D Dal Ben, C Lambertucci, A Spinaci, R Volpini, ... Cells 9 (7), 1739, 2020 | 38 | 2020 |
| The G Protein‐Coupled Receptor GPR17: Overview and Update G Marucci, D Dal Ben, C Lambertucci, C Santinelli, A Spinaci, A Thomas, ... ChemMedChem 11 (23), 2567-2574, 2016 | 32 | 2016 |
| Non-nucleoside agonists of the adenosine receptors: an overview D Dal Ben, C Lambertucci, M Buccioni, A Martí Navia, G Marucci, ... Pharmaceuticals 12 (4), 150, 2019 | 19 | 2019 |
| The anti-inflammatory and pain-relieving effects of AR170, an adenosine A3 receptor agonist, in a rat model of colitis L Antonioli, E Lucarini, C Lambertucci, M Fornai, C Pellegrini, L Benvenuti, ... Cells 9 (6), 1509, 2020 | 18 | 2020 |
| Modifications on the amino-3, 5-dicyanopyridine core to obtain multifaceted adenosine receptor ligands with antineuropathic activity M Betti, D Catarzi, F Varano, M Falsini, K Varani, F Vincenzi, S Pasquini, ... Journal of Medicinal Chemistry 62 (15), 6894-6912, 2019 | 18 | 2019 |
| P2X3 receptor ligands: structural features and potential therapeutic applications A Spinaci, M Buccioni, D Dal Ben, G Marucci, R Volpini, C Lambertucci Frontiers in pharmacology 12, 2021 | 14 | 2021 |
| New potent and selective A1 adenosine receptor antagonists as potential tools for the treatment of gastrointestinal diseases C Lambertucci, G Marucci, D Dal Ben, M Buccioni, A Spinaci, S Kachler, ... European Journal of Medicinal Chemistry 151, 199-213, 2018 | 14 | 2018 |
| The Length and Flexibility of the 2‐Substituent of 9‐Ethyladenine Derivatives Modulate Affinity and Selectivity for the Human A2A Adenosine Receptor A Thomas, M Buccioni, D Dal Ben, C Lambertucci, G Marucci, C Santinelli, ... ChemMedChem 11 (16), 1829-1839, 2016 | 14 | 2016 |
| Casein Kinase 1δ Inhibitors as Promising Therapeutic Agents for Neurodegenerative Disorders D Catarzi, F Varano, E Vigiani, C Lambertucci, A Spinaci, R Volpini, ... Current Medicinal Chemistry, 2022 | 13 | 2022 |
| Combined Therapy of A1AR Agonists and A2AAR Antagonists in Neuroinflammation G Marucci, D Dal Ben, C Lambertucci, A Martí Navia, A Spinaci, R Volpini, ... Molecules 26 (4), 1188, 2021 | 13 | 2021 |
| Ex-vivo absorption study of lysine R-lipoate salt, a new pharmaceutical form of R-ALA F Amenta, M Buccioni, D Dal Ben, C Lambertucci, AM Navia, ... European Journal of Pharmaceutical Sciences 118, 200-207, 2018 | 13 | 2018 |
| GPR17 receptor modulators and their therapeutic implications: review of recent patents G Marucci, D Dal Ben, C Lambertucci, A Martí Navia, A Spinaci, R Volpini, ... Expert Opinion on Therapeutic Patents 29 (2), 85-95, 2019 | 12 | 2019 |
| 2′, 3′-O-Substituted ATP derivatives as potent antagonists of purinergic P2X3 receptors and potential analgesic agents D Dal Ben, A Marchenkova, A Thomas, C Lambertucci, A Spinaci, ... Purinergic signalling 13 (1), 61-74, 2017 | 12 | 2017 |
| New substituted 9-propyladenine derivatives as A 2A adenosine receptor antagonists C Lambertucci, M Buccioni, D Dal Ben, S Kachler, G Marucci, A Spinaci, ... Medchemcomm 6 (5), 963-970, 2015 | 12 | 2015 |
| Simulation and Comparative Analysis of Different Binding Modes of Non‐nucleoside Agonists at the A2A Adenosine Receptor D Dal Ben, M Buccioni, C Lambertucci, G Marucci, C Santinelli, A Spinaci, ... Molecular Informatics 35 (8-9), 403-413, 2016 | 10 | 2016 |
| A2A Adenosine Receptor Antagonists and their Potential in Neurological Disorders. C Lambertucci, G Marucci, D Catarzi, V Colotta, B Francucci, A Spinaci, ... Current Medicinal Chemistry, 2022 | 9 | 2022 |
| Investigation on 2′,3′-O-Substituted ATP Derivatives and Analogs as Novel P2X3 Receptor Antagonists D Dal Ben, M Buccioni, C Lambertucci, G Marucci, A Spinaci, ... ACS medicinal chemistry letters 10 (4), 493-498, 2018 | 9 | 2018 |
| Approaches for designing and discovering purinergic drugs for gastrointestinal diseases D Dal Ben, L Antonioli, C Lambertucci, A Spinaci, M Fornai, ... Expert Opinion on Drug Discovery 15 (6), 687-703, 2020 | 8 | 2020 |
| A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable? A Spinaci, C Lambertucci, M Buccioni, D Dal Ben, C Graiff, MC Barbalace, ... Molecules 27 (8), 2386, 2022 | 7 | 2022 |
